Some cancers lack the ability to effectively repair DNA damage due to mutations in genes like BRCA1 or BRCA2. Drugs known as PARP inhibitors can exploit this deficiency by further inhibiting DNA repair, leading to the accumulation of lethal DNA damage in cancer cells while sparing normal cells.
